Innoviva to Participate in the BofA Securities Health Care Conference
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
Innoviva to Participate in the Cantor Global Healthcare Conference
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
Innoviva Appoints Stephen Basso as Chief Financial Officer